• ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01

    Monday June 5th 2023

  • Biotalys continues to demonstrate strength of first biocontrol in latest global field trials

    Friday June 2nd 2023

  • Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema

    Friday May 26th 2023

  • Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis

    Wednesday May 24th 2023

  • Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure

    Tuesday May 2nd 2023

  • Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

    Thursday April 27th 2023

  • VIB and Ghent University develop new mRNA vaccines against bacterial infections

    Wednesday April 26th 2023

  • Bimekizumab Phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks

    Monday March 20th 2023

  • Your news here?

  • Oxurion provides update on recruitment for KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema and announces Board changes

    Tuesday March 14th 2023

  • Mithra announces promising topline safety results from Donesta® Phase 3 Study in North America

    Monday March 6th 2023

  • Mithra announces compelling initial preclinical data in its research collaboration on novel tyrosine kinase inhibitors with BCI Pharma

    Thursday March 2nd 2023


Strategic Partners